These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 10459813)
1. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion. Souza LC; Campa A J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813 [TBL] [Abstract][Full Text] [Related]
3. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902 [TBL] [Abstract][Full Text] [Related]
4. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
5. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. Souza LC; Maranhão RC; Schreier S; Campa A J Antimicrob Chemother; 1993 Jul; 32(1):123-32. PubMed ID: 8226403 [TBL] [Abstract][Full Text] [Related]
6. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593 [TBL] [Abstract][Full Text] [Related]
7. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723 [TBL] [Abstract][Full Text] [Related]
8. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072 [TBL] [Abstract][Full Text] [Related]
9. Supramolecular Chitosan Micro-Platelets Synergistically Enhance Anti-Candida albicans Activity of Amphotericin B Using an Immunocompetent Murine Model. Grisin T; Bories C; Bombardi M; Loiseau PM; Rouffiac V; Solgadi A; Mallet JM; Ponchel G; Bouchemal K Pharm Res; 2017 May; 34(5):1067-1082. PubMed ID: 28168390 [TBL] [Abstract][Full Text] [Related]
10. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. van Etten EW; van den Heuvel-de Groot C; Bakker-Woudenberg IA J Antimicrob Chemother; 1993 Nov; 32(5):723-39. PubMed ID: 8125837 [TBL] [Abstract][Full Text] [Related]
11. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. van Etten EW; Chander HR; Snijders SV; Bakker-Woudenberg IA J Antimicrob Chemother; 1995 Dec; 36(6):961-74. PubMed ID: 8821595 [TBL] [Abstract][Full Text] [Related]
12. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. Kirsh R; Goldstein R; Tarloff J; Parris D; Hook J; Hanna N; Bugelski P; Poste G J Infect Dis; 1988 Nov; 158(5):1065-70. PubMed ID: 3183418 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826 [TBL] [Abstract][Full Text] [Related]
14. Amphotericin B lipid complex. Rapp RP; Gubbins PO; Evans ME Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444 [TBL] [Abstract][Full Text] [Related]
15. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles. Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532 [TBL] [Abstract][Full Text] [Related]
16. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis. Levy MY; Polacheck I; Barenholz Y; Benita S J Med Vet Mycol; 1993; 31(3):207-18. PubMed ID: 8360812 [TBL] [Abstract][Full Text] [Related]
17. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Collette N; van der Auwera P; Lopez AP; Heymans C; Meunier F Antimicrob Agents Chemother; 1989 Mar; 33(3):362-8. PubMed ID: 2658785 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Wasan KM; Conklin JS Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections. Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151 [TBL] [Abstract][Full Text] [Related]
20. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature. Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]